
WKD.SMRT provides a user-friendly, in-home IoT+AI platform designed to deliver superior data for clinical trials, particularly for neurodegenerative diseases and motor dysfunction. Their solution addresses the critical bottleneck of clinical trials, which are often slow, costly, and produce inadequate data. The platform combines multiple IoT sensor nodes with edge computing for AI processing, a tablet for patient interaction, and a hub for connectivity, delivering data-as-a-service via secure APIs. Founded by professors and CTOs from MIT and Dartmouth, WKD.SMRT leverages smart-home technologies and machine learning to accelerate the drug development process by providing more sensitive, complete, and real-world data on patient function.

WKD.SMRT provides a user-friendly, in-home IoT+AI platform designed to deliver superior data for clinical trials, particularly for neurodegenerative diseases and motor dysfunction. Their solution addresses the critical bottleneck of clinical trials, which are often slow, costly, and produce inadequate data. The platform combines multiple IoT sensor nodes with edge computing for AI processing, a tablet for patient interaction, and a hub for connectivity, delivering data-as-a-service via secure APIs. Founded by professors and CTOs from MIT and Dartmouth, WKD.SMRT leverages smart-home technologies and machine learning to accelerate the drug development process by providing more sensitive, complete, and real-world data on patient function.
Company: WKD.SMRT
Product: In-home IoT+AI platform for continuous functional monitoring in clinical trials
Founded: 2019
Headquarters: Cambridge, Massachusetts
Notable partners: Biogen; Massachusetts General Hospital; PharmStars
Founder / CEO: Michael A. M. Davies
Clinical-trial data quality and monitoring for neurodegenerative and motor-dysfunction diseases
2019
DeepTech
Participation in PharmStars accelerator noted on company materials